U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H25N7O3
Molecular Weight 471.5121
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DABIGATRAN

SMILES

Cn1c2ccc(cc2nc1CNc3ccc(cc3)C(=N)N)C(=O)N(CCC(=O)O)c4ccccn4

InChI

InChIKey=YBSJFWOBGCMAKL-UHFFFAOYSA-N
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)

HIDE SMILES / InChI

Molecular Formula C25H25N7O3
Molecular Weight 471.5121
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s007lbl.pdf https://www.pradaxa.com/

Dabigatran ethyl ester is a one of the intermediate, which is formed during metabolic reactions from dabigatran etexilate. Dabigatran ethyl ester forming under the action of intestinal carboxylesterase 2 (CES2) further is hydrolyzed by CES1 with formation of active drug, thrombin inhibitor, dabigatranand. Dabigatran ethyl ester is a much stronger inhibitor of ribosyldihydronicotinamide dehydrogenase, than dabigatran.

CNS Activity

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
PRADAXA

Approved Use

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery

Launch Date

1.28735995E12
Primary
PRADAXA

Approved Use

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery

Launch Date

1.28735995E12
Preventing
PRADAXA

Approved Use

PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (1.1) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days (1.2) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated (1.3) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery

Launch Date

1.28735995E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
348 ng/mL
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2232 ng × h/mL
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.3 h
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
150 mg 2 times / day steady-state, oral
dose: 150 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DABIGATRAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 3 times / day single, oral
Highest studied dose
Dose: 400 mg, 3 times / day
Route: oral
Route: single
Dose: 400 mg, 3 times / day
Sources: Page: p.301
healthy, 18–45
n = 8
Health Status: healthy
Age Group: 18–45
Sex: M
Population Size: 8
Sources: Page: p.301
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.301
healthy, 18–45
n = 6
Health Status: healthy
Age Group: 18–45
Sex: M
Population Size: 6
Sources: Page: p.301
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Disc. AE: C-reactive protein increased, Alanine aminotransferase increase...
AEs leading to
discontinuation/dose reduction:
C-reactive protein increased (7.14%)
Alanine aminotransferase increase (7.14%)
Haematuria (7.14%)
Epistaxis (7.14%)
Haemorrhoidal haemorrhage (7.14%)
Sources: Page: p.605
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.5
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.5
Disc. AE: Bleeding, Gastrointestinal disorder NOS...
AEs leading to
discontinuation/dose reduction:
Bleeding
Gastrointestinal disorder NOS
Sources: Page: p.5
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.6
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.6
Disc. AE: Bleeding...
AEs leading to
discontinuation/dose reduction:
Bleeding (grade 5, 0.07%)
Sources: Page: p.6
150 mg 2 times / day multiple, oral (max)
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Sources: Page: p.1
Disc. AE: Spinal epidural hematoma, Bleeding...
AEs leading to
discontinuation/dose reduction:
Spinal epidural hematoma
Bleeding (grade 3-5)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Alanine aminotransferase increase 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
C-reactive protein increased 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Epistaxis 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Haematuria 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Haemorrhoidal haemorrhage 7.14%
Disc. AE
150 mg 6 times / day multiple, oral
Recommended
Dose: 150 mg, 6 times / day
Route: oral
Route: multiple
Dose: 150 mg, 6 times / day
Sources: Page: p.605
healthy, 18–45
n = 14
Health Status: healthy
Age Group: 18–45
Sex: M+F
Population Size: 14
Sources: Page: p.605
Bleeding Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.5
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.5
Gastrointestinal disorder NOS Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.5
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.5
Bleeding grade 5, 0.07%
Disc. AE
150 mg 2 times / day multiple, oral
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.6
unhealthy
n = 6059
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Population Size: 6059
Sources: Page: p.6
Spinal epidural hematoma Disc. AE
150 mg 2 times / day multiple, oral (max)
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Sources: Page: p.1
Bleeding grade 3-5
Disc. AE
150 mg 2 times / day multiple, oral (max)
Recommended
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Non-valvular atrial fibrillation|deep venous thrombosis|pulmonary embolism
Sources: Page: p.1
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no [IC50 >100 uM]
no
no
no
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no (co-administration study)
Comment: Coadministration of Atorvastatin (CYP3A4 & P-gp inhibitor, 400 mg QD x 4 days) with Dabigatran metexilate mesylate (150 mg BID x 3 days and 150 mg QD on Day 4) decreased total Dabigatran AUCtau,ss by 58% and Cmax,ss by 50%., Coadministration of Clarithromycin (CYP3A4 & P-gp inhibitor, 500 mg BID x 5 days & 500 mg QD on Day 6) with Dabigatran metexilate mesylate (150 mg QD on Day 6) increased total Dabigatran AUCinf by 19% and Cmax by 15%., Coadministration of Rifampicin (CYP3A4 & P-gp inducer, 600 mg QD x 7 days in the night) with Dabigatran metexilate mesylate (150 mg QD on Day 8 morning) decreased total Dabigatran AUCinf by 67% and Cmax by 66%., Coadministration of Ketoconazole (CYP3A4 & P-gp inhibitor, 400mg QD ) with Dabigatran metexilate mesylate (150 mg QD) increased total Dabigatran AUCinf by 138% and Cmax by 135%.
Page: (ClinPharm) 13, (PMDA_A100_1 Japanese) 32, 40-41, (PMDA_I100_1 Japanese) 33
no
no (co-administration study)
Comment: Caco-2 cells, Efflux ratio = 1.09 (3 mcM), 0.95 (300 mcM); MDR1-LLC-PK1 cells, Efflux ratio = 1.35 (10 mcM); Coadministration of Amiodarone (P-gp & CYP2C9 inhibitor, 600 mg QD on Day 4) with Dabigatran metexilate mesylate (150 mg BID x 3 days and 150 mg QD on Day 4) increased total Dabigatran AUCtau,ss by 58% and Cmax by 50%., Coadministration of Verapamil (P-gp inhibitor, 120 mg single or multiple doses, or 240 mg single dose) with Dabigatran metexilate mesylate (150 mg single dose) increased total Dabigatran AUCinf by 39~143% and Cmax by 12~179%., Coadministration of Quinidine (200 mg every 2 hr x 5 on Day 3 (3 hr after the first Dabigatran dose), P-gp inhibitor) with Dabigatran metexilate mesylate (150 mg BID x 3 days (2nd dose on Day 3 was administrated 1 hr after the final Quinidine dose) increased total Dabigatran AUCtau,ss by 53% and Cmax,ss by 56%., Coadministration of Ketoconazole (CYP3A4 & P-gp inhibitor, 400mg QD ) with Dabigatran metexilate mesylate (150 mg QD) increased total Dabigatran AUCinf by 138% and Cmax by 135%., Coadministration of Atorvastatin (CYP3A4 & P-gp inhibitor, 400 mg QD x 4 days) with Dabigatran metexilate mesylate (150 mg BID x 3 days and 150 mg QD on Day 4) decreased total Dabigatran AUCtau,ss by 58% and Cmax,ss by 50%., Coadministration of Clarithromycin (CYP3A4 & P-gp inhibitor, 500 mg BID x 5 days & 500 mg QD on Day 6) with Dabigatran metexilate mesylate (150 mg QD on Day 6) increased total Dabigatran AUCinf by 19% and Cmax by 15%., Coadministration of Rifampicin (CYP3A4 & P-gp inducer, 600 mg QD x 7 days in the night) with Dabigatran metexilate mesylate (150 mg QD on Day 8 morning) decreased total Dabigatran AUCinf by 67% and Cmax by 66%.
Page: 54-55, 56-57, (ClinPharm) 12, 13, 33-36, (PMDA_A100_1 Japanese) 33, 39, 40-41, (PMDA_I100_1 Japanese) 66, (PMDA_K103_1 Japanese) 152-156
yes [Km 371.4 uM]
yes [Km 511.7 uM]
yes [Km 987.3 uM]
Tox targets
PubMed

PubMed

TitleDatePubMed
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.
2008
[Perioperative venous thromboembolism prophylaxis: short review and recommendations].
2008 Dec
[New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].
2008 Nov
[Anaesthesia and thromboembolic disease].
2008 Nov
Recently published papers: Novel therapies in chronic obstructive pulmonary disease, cardiac chemicals and intensive care outcomes.
2009
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
2009
The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.
2009
Use of anticoagulants in elderly patients: practical recommendations.
2009
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
2009
[New anticoagulants for secondary haemostasis--anti IIa inhibitors].
2009 Aug
Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT.
2009 Dec
[New oral anticoagulants. Consequences for perioperative coagulation diagnostics and therapy].
2009 Dec
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.
2009 Dec
Dabigatran versus warfarin in the treatment of acute venous thromboembolism.
2009 Dec 10
Dabigatran versus warfarin in patients with atrial fibrillation.
2009 Dec 31
Dabigatran versus warfarin in patients with atrial fibrillation.
2009 Dec 31
Dabigatran versus warfarin in patients with atrial fibrillation.
2009 Dec 31
Dabigatran versus warfarin in patients with atrial fibrillation.
2009 Dec 31
Dabigatran: new drug. Continue to use heparin, a better-known option.
2009 Jun
[Venous thromboembolism prophylaxis in orthopaedics and traumatology].
2009 Mar
The prevention of hospital-acquired venous thromboembolism in the United Kingdom.
2009 Mar
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
2009 May
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
2009 May
[Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].
2009 May-Jun
[Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism].
2009 May-Jun
[The results of the RE-lY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation].
2009 Nov
Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
2009 Nov
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts.
2009 Nov
The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin.
2009 Nov
Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate.
2009 Nov 3
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
2009 Oct
[New developments in antithrombotic care].
2009 Sep
[Dabigatran: clinical pharmacology].
2009 Sep
[Perspectives in cardiology: evidence of efficacy in atrial fibrillation and hopes in acute coronary syndrome].
2009 Sep
[Anticoagulants drugs direct trombin inhibitors].
2009 Sep
Dabigatran versus warfarin in patients with atrial fibrillation.
2009 Sep 17
Dabigatran: safer, more effective and easier to use than warfarin.
2009 Sep-Oct
Oral antithrombotic inhibitors: dabigatran etexilate, meeting an unmet need?
2009 Sep-Oct
Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
2009 Sep-Oct
Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
2010 Apr
[Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].
2010 Feb
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
2010 Feb
New oral anticoagulants: a practical guide for clinicians.
2010 Feb
The potential benefits of low-molecular-weight heparins in cancer patients.
2010 Jan 14
The new oral anticoagulants.
2010 Jan 7
Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in scleroderma.
2010 Jun
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
2010 Mar
Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
2010 Mar
New anticoagulants for prevention and treatment of venous thromboembolism.
2010 May
[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].
2010 Sep
Patents

Sample Use Guides

Usual Adult Dose for Deep Vein Thrombosis - Prophylaxis Recommended doses: 150 mg orally twice a day Usual Adult Dose for Prevention of Thromboembolism in Atrial Fibrillation Recommended doses: 150 mg orally twice a day Usual Adult Dose for Deep Vein Thrombosis/Pulmonary Embolism Prophylaxis Following Hip Replacement Surgery 110 mg orally 1 to 4 hours after surgery and after hemostasis has been achieved, then 220 mg orally once a day for 28 to 35 days
Route of Administration: Oral
Dabigatran at higher concentrations (500 and 1000 nM) potently inhibited thrombus formation. In platelet-poor plasma, dabigatran at 250 and 500 nM efficiently prolonged the lag time (LT) and moderately reduce peak height (PH) of TG.
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:41:51 UTC 2021
Edited
by admin
on Fri Jun 25 23:41:51 UTC 2021
Record UNII
I0VM4M70GC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DABIGATRAN
INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
BIBR 953 ZW
Code English
BIBR-953-ZW
Code English
N-((2-((P-AMIDINOANILINO)METHYL)-1-METHYL-5-BENZIMIDAZOLYL)CARBONYL)-N-2-PYRIDYL-.BETA.-ALANINE
Common Name English
DABIGATRAN [WHO-DD]
Common Name English
DABIGATRAN [USAN]
Common Name English
3-(((2-(((4-CARBAMIMIDOYLPHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)(PYRIDIN-2-YL)AMINO)PROPANOIC ACID
Systematic Name English
DABIGATRAN [MART.]
Common Name English
DABIGATRAN [INN]
Common Name English
DABIGATRAN [VANDF]
Common Name English
.BETA.-ALANINE, N-((2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-
Systematic Name English
DABIGATRAN [MI]
Common Name English
PRADAXA (DABIGATRAN)
Brand Name English
BIBR-953
Code English
Classification Tree Code System Code
NCI_THESAURUS C263
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
LOINC 68980-2
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
LOINC 74220-5
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
LIVERTOX 255
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
Code System Code Type Description
EVMPD
SUB25417
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
MESH
C554682
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
ChEMBL
CHEMBL48361
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
NCI_THESAURUS
C73224
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
PUBCHEM
216210
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
WIKIPEDIA
DABIGATRAN
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
RXCUI
1546356
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY RxNorm
CAS
211914-51-1
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
LACTMED
Dabigatran
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
MERCK INDEX
M4064
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY Merck Index
EPA CompTox
211914-51-1
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
FDA UNII
I0VM4M70GC
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
DRUG BANK
DB14726
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
INN
8027
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
HSDB
8062
Created by admin on Fri Jun 25 23:41:51 UTC 2021 , Edited by admin on Fri Jun 25 23:41:51 UTC 2021
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
INHIBITOR -> TARGET
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
REVERSIBLE
IC50
Related Record Type Details
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
URINE
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
TRACE AMOUNT
PLASMA
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA; URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
URINE
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
TRACE AMOUNT
PLASMA
METABOLITE -> PARENT
after p.o. administration of 200 mg of 14C dabigatran etexilate in healthy volunteers
FECAL
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
URINE
METABOLITE -> PARENT
after i.v. infusion of 5 mg of 14C dabigatran in healthy volunteers
FECAL
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC INTRAVENOUS ADMINISTRATION

DOSE

Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC